Amlodipine/​Atorvastatin

DEA Class; Rx

Common Brand Names; Caduet

• Calcium Channel Blockers; 
• Lipid-Lowering Agents, Statins; 
• Calcium Channel Blockers, Dihydropyridine; 
• HMG-CoA Reductase Inhibitors

Combination calcium-channel blocker and HMG-CoA reductase inhibitor; used for HTN or angina with hyperlipidemia in patients who were previously receiving the individually titrated drug components

Indicated for the treatment of hypertension or coronary artery disease including angina (chronic stable angina or variant angina) in patients with coexisting hyperlipoproteinemia (hypercholesterolemia, type IV hypertriglyceridemia, or type III hyperlipoproteinemia) and/or patients at risk for complications of coronary artery disease (stroke prophylaxis, myocardial infarction prophylaxis).

Hypersensitivity to amlodipine or atorvastatin

Active liver disease, or unexplained elevated transminases

Amlodipine

• Peripheral edema (2-15%)

• Palpitation (1-5%)

• Dizziness (1-3%)

• Flushing (1-5%)

• Somnolence (1-2%)

• Rash (1-2%)

• Fatigue (5%)

• Pruritus (1-2%)

• Male sexual dysfunction (1-2%)

• Nausea (3%)

• Dyspepsia (1-2%)

• Dyspnea (1-2%)

• Weakness (1-2%)

Atorvastatin

• Arthralgia (4-12%)

• Diarrhea (5-14%)

• Nasopharingitis (4-13%)

• Nausea (4-7%)

• Dyspepsia (3-6%)

• Increased transaminases (2-3% with 80 mg/day)

• Urinary tract infection (4-8%)

• Insomnia (1-5%)

• Myalgia (3-8%)

• Musculoskeletal pain (2-5%)

• Respiratory pharyngeal pain (1-4%)

Symptomatic hypotension is possible with use of amlodipine, particularly in patients with severe aortic stenosis; because of gradual onset of action, acute hypotension is unlikely

Use caution in congestive heart failure

Persistent progressive dermatologic reactions

Worsening angina and acute myocardial infarction can develop after starting or increasing dose of amlodipine, particularly in patients with severe obstructive coronary artery disease

Heavy alcohol use, history of liver disease, renal failure

Adverse reactions associated with atorvastatin therapy reported including anaphylaxis, angioneurotic edema, bullous rashes (including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis), rhabdomyolysis, myositis, fatigue, tendon rupture, fatal and non-fatal hepatic failure, dizziness, depression, peripheral neuropathy, pancreatitis and interstitial lung disease

Atorvastatin

• Owing to HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, fetal harm may occur when administered to pregnant females; discontinue therapy as soon as pregnancy is recognized; limited published data are insufficient to determine a drug-associated risk of major congenital malformations or miscarriage

Amlodipine

• Limited available data based on postmarketing reports with use in pregnant female are not sufficient to inform a drug-associated risk for major birth defects and miscarriage

Lactation

There is no available information on effects of drug on breastfed infant or on milk production